期刊
JNP-JOURNAL FOR NURSE PRACTITIONERS
卷 13, 期 6, 页码 418-424出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.nurpra.2016.08.023
关键词
GLP-1 receptor agonists; DPP-4 inhibitors; incretin therapy; primary care; type 2 diabetes mellitus
类别
Glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase 4 inhibitors ate 2 of 6 second-line medication options in diabetes management according to the 2016 American Diabetes Association guidelines. Providers must take many factors into consideration when choosing a tteatment regimen, including patient preference, cost and insurance coverage, efficacy, and tolerability. Side effects, such as hypoglycemia and weight gain; often contribute to lack of control and poor adherence. Glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase 4 inhibitors are well tolerated options that improve glycemic control with a low incidence of hypoglycemia and weight gain. In this article we review the similarities, differences, advantages, and disadvantages of the incretin therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据